HitGen has established an industry-leading drug discovery platform for small molecules and nucleic acid drugs centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen DELs contain more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against both precedented and unprecedented classes of biological targets.
HitGen founder Dr. Jin Li and Vernalis chief scientist Professor Rod Hubbard will join hands to illustrate advancing innovative drug discovery by DNA Encoded Library and FBDD/SBDD methods.
Jin Li founded HitGen in 2012, and has over 30 years’ biopharmaceutical experience. He previously held global research leadership roles at AstraZeneca, including responsibility for molecular design, synthesis, screening, and major external collaborations. HitGen has become one of the most impactful companies in the field of innovative drug discovery powered by its DEL platform, and collaborates with the world’s leading pharmaceutical, biotech, and research organizations.
Rod Hubbard has been working with methods for analysis and exploitation of protein structure for over 40 years. In the 1980s, he was a pioneer in the development of molecular graphics and modelling methods that were commercialized by Accelrys. In the 1990s, he collaborated with many pharmaceutical companies on the structure of important drug targets while developing new ideas in how to use structural information in drug discovery. In 1997, he was a founding SAB member of Vernalis, guiding development of fragment-based discovery methods that have been applied to many tens of targets. His current role is to initiate, build and coordinate external collaborations at Vernalis which have generated 5 pre-clinical candidates in the last 4 years. He is recognized as an international leader in the development and promotion of fragment-based discovery and consults with pharmaceutical and technology companies around the world.
NOW AVAILABLE ON-DEMAND